It also resulted in an increase in median progression-free survival by 4.9 months (6.1 months versus 11 months), which was associated with improved overall survival (hazard ratio 0.674) in the combination arm relative to paclitaxel monotherapy, although this difference did not reach statistical significance.
1
—
—